Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged Over 3 Years.
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
- 25 Feb 2019 Status changed from recruiting to completed.
- 08 Nov 2018 According to a Sinovac Biotech media release, the company expects to complete this study by 2018.
- 11 May 2018 According to a Sinovac Biotech media release, this trial was initiated in the fourth quarter of 2017.